News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week In Review: Jiangsu Aosaikang Pharma Delays China IPO


1/20/2014 5:39:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

January 18, 2014 --Jiangsu Aosaikang Pharma temporarily delayed its $669 million China IPO, saying it was “relatively large,” which didn’t exactly explain the holdup; Changchun High & New Technology Industries paid $4.8 million for a 25% interest in Dutch vaccine maker Mucosis; Wuhan Kindstar Clinical Diagnostics in-licensed a lung cancer test from Germany’s Epigenomics; Thermo Fisher was OK’d by China for its $13.6 billion acquisition of Life Technologies; TaiGen Biotech of Taiwan and Beijing out-licensed Russian rights for its novel antibiotic to R-Pharm of Russia; China issued additional regulations for conducting IPOs under its new “market-oriented” system; Actavis will quit China because it considers the business environment too difficult and the potential profits too small; GlaxoSmithKline said its China revenues turned higher in the fourth quarter of 2013 after dropping a disastrous 61% in Q3; US-based Neuralstem treated its first patient in a China stem cell trial of a stroke treatment; and EntreMed filed a clinical trial application for a China Phase II trial of its ovarian cancer treatment. More details….

Stock Symbols: (SHE: 300361) (F: ECX, OTC: EPGNY) (NYSE: TMO) (NSDQ: LIFE) (NYSE: ACT) (NYSE: GSK) (NYSE: CUR) (NSDQ: ENMD)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES